AI stock analysis · Drug Manufacturers - Specialty & Generic · Last analyzed Jul 7, 2026
Compass Score
2.0/5
Call
Avoid
Price
$4.92
AI Target
$7.40 +50.3%
AI Analyst Summary
Bausch Health presents a deeply discounted forward valuation (1.2x forward P/E) and strong revenue momentum (+11.7% YoY), driven by its diversified specialty pharma and eye-health portfolio — suggesting meaningful upside if the company successfully executes its path to sustained profitability. However, the company remains loss-making on a trailing basis, carries a significant debt burden, and has delivered EPS beats in only 2 of the last 4 quarters, reflecting execution risk. The key risk is that ongoing legal liabilities and leverage constrain financial flexibility and delay any re-rating.
Catalysts
Bausch + Lomb subsidiary progress — any IPO completion or stake monetization could unlock significant balance sheet value and serve as a near-term re-rating event.
Revenue growth acceleration in core specialty pharma segments could demonstrate bottom-line conversion in upcoming quarterly results, turning the earnings trend positive.
Debt refinancing or restructuring milestones that reduce interest expense burden could materially improve forward EPS estimates and drive analyst upgrades from Hold to Buy.
Risks
Heavy debt load (estimated >$20B in total liabilities) constrains capital allocation and raises refinancing risk in a higher-for-longer rate environment.
Ongoing litigation and legal settlements — including opioid-related and other legacy liabilities — could result in material cash outflows that further pressure the balance sheet.
Failure to monetize or separate Bausch + Lomb as planned could eliminate a key re-rating catalyst and weigh on the stock for an extended period.
Fundamentals
PeN/A (loss-making); Forward P/E: 1.2x · 3.0/5
No trailing P/E due to losses, but the forward P/E of 1.2x is extremely compressed — deeply below the healthcare sector median, though driven by debt burdens and restructuring rather than pure earnings power. Neutral pending profitability confirmation.
PegPEG: 0.01 · 5.0/5
PEG of 0.01 is statistically near-zero, likely distorted by earnings base normalization or one-time items. On face value it signals exceptional value relative to growth, but must be interpreted cautiously given the loss-making backdrop.
Analyst RatingHold consensus (3.0) · 3.0/5
Consensus sits exactly at 3.0 with 7 Hold ratings and zero Buy or Sell recommendations. Analysts are squarely on the fence — no conviction either way. Capped at 3 given the neutral-only distribution.
Earnings growth is unavailable due to ongoing losses, which is a meaningful headwind. Revenue growth of 11.7% is encouraging and shows commercial momentum, but without bottom-line conversion the earnings trend scores below average.
Price Target Beat2 of 4 quarters beat · 2.0/5
Only 2 of the last 4 quarters resulted in EPS beats — a below-average execution rate. This suggests inconsistent earnings delivery and limited visibility into near-term profitability.
ManagementMixed execution · 2.0/5
A 50% EPS beat rate, persistent losses, and a purely neutral analyst consensus collectively signal mixed management execution. Revenue growth is a positive, but capital allocation remains constrained by a heavy debt load and ongoing legal liabilities.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.